Long, Noncoding RNA SRA Induces Apoptosis of β-Cells by Promoting the IRAK1/LDHA/Lactate Pathway

Area of Science:

• Endocrinology
• Molecular Biology
• Immunology

Background:

• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in disease pathogenesis.
• LncRNA steroid receptor RNA activators (SRAs) have been linked to Type 1 diabetes mellitus (T1D)-associated β-cell destruction, but their specific functions are unclear.

Purpose of the Study:

• To investigate the regulatory role of LncRNA SRA in pancreatic β-cells within the context of T1D.
• To elucidate the molecular mechanisms by which LncRNA SRA influences β-cell function and survival.

Main Methods:

• Quantitative analysis of LncRNA SRA expression in plasma and peripheral blood mononuclear cells (PBMCs) from T1D patients.
• In vitro studies involving high-glucose and recombinant interleukin-2 treatments on β-cells.
• Assessment of LncRNA SRA's interaction with microRNA-146b (miR-146b).
• Evaluation of the impact of LncRNA SRA silencing on Treg function, cellular metabolism, and β-cell apoptosis.

Main Results:

• LncRNA SRA was significantly upregulated in T1D patient samples and by high-glucose conditions.
• LncRNA SRA functions as a miR-146b sponge, inhibiting its activity.
• Silencing LncRNA SRA enhanced Treg function, normalized metabolic parameters (reduced lactate and ROS, increased ATP), and decreased β-cell apoptosis.
• Elevated plasma LncRNA SRA and lactate levels correlated with poor glycemic control (HbA1c) in T1D patients.
• LncRNA SRA promotes T1D pathogenesis via miR-146b inhibition, activating the IRAK1/LDHA/pLDHA pathway.

Conclusions:

• LncRNA SRA plays a critical role in T1D pathogenesis by impairing β-cell function and survival.
• Targeting LncRNA SRA may represent a novel therapeutic strategy for managing T1D.
• The LncRNA SRA/miR-146b axis is a key regulator of β-cell function in T1D.